Associação do cortisol piloso, gravidade e qualidade de vida em cães com dermatite atópica após terapia com lokivetmab

• Ano de defesa: 2021
• Autor(a) principal: Vanessa Stuart Marques
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; Brasil; VET - DEPARTAMENTO DE CLÍNICA E CIRURGIA; Programa de Pós-Graduação em Ciência Animal; UFMG
• Palavras-chave em Português: Câes; Prurido; Dermatologia veterinária; Ciência animal
• Link de acesso: http://hdl.handle.net/1843/39010; https://orcid.org/0000-0003-3890-0728

Canine atopic dermatitis is an inflammatory and pruritic skin disease, with clinical characteristics associated to IgE antibodies, most commonly directed against environmental allergens which impacts the quality of life in affected animals and their owners. Treatment is multifaceted and must be adapted to each patient individually. Currently, a medication based on caninized monoclonal antibody (mAb), called lokivetmab, has shown promise for controlling of the signs of the disease, as it neutralizes interleukin (IL)-31, a cytokine that plays an important role in the pathogenesis of atopy. The impact of dermatological diseases on the affected dog’s life and its owners has only been studied in recent years through validated questionnaires. This additional measurement tool has been shown to be important for evaluating the therapeutic success of interventions in atopic dermatitis, as clinical improvement may not correlate with an increased quality of life. A non-invasive and objective method, currently considered a promising indicator of the quality of life in atopic patients, is the measurement of cortisol incorporated into the hair follicle. This study aimed to evaluate and compare the clinical severity of the disease, quality of life and hair cortisol levels in atopic dogs after lokivetmab therapy. Ten atopic dogs treated at the dermatology service of the Veterinary Hospital of the Veterinary School from UFMG were selected. Severity of the disease was assessed using the canine atopic dermatitis extent and severity index (CADESI)-04 and pruritus visual analog scale (pVAS) scores, quality of life using a validated questionnaire, and hair cortisol levels in these patients, before and after lokivetmab therapy. It conclues that treatment with lokivetmab was not able to reduce the extent and severity of dermal lesions in atopic patients, but it significantly improved the pruritus and quality of life of dogs and their owners; and the impact on the quality of life of both is worse the more itchy the patient were. There was no correlation observed between hair cortisol levels, severity of the disease and quality of life of atopic dogs after lokivetmab. However, lower concentrations were found after the second application of the medication. More studies are needed on the levels of hair cortisol in these patients and its role as a biomarker of stress and quality of life, and even more, its contribution to the perpetuation of the disease.